» Articles » PMID: 2994703

Three Months Treatment with Chemotherapy and Radiotherapy for Small Cell Lung Cancer

Overview
Journal Br J Cancer
Specialty Oncology
Date 1985 Sep 1
PMID 2994703
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Fifty-five patients with inoperable but limited stage small cell carcinoma of the bronchus and a further 15 patients with contra lateral neck nodes, pleural effusions and marrow involvement were entered into the study and treated. The 3 month treatment regimen comprised 3 courses of etoposide with cyclophosphamide at 2.5 gm-2 followed by methotrexate and radiotherapy, no maintenance treatment was given. The complete response rate in the total patient group was 54% and the partial response rate 21%. The median survival was 11 months for the 70 patients, 15 months for the complete responders, and those patients with a bronchoscopically confirmed complete response survived significantly longer. There was no significant difference between the patients with strictly limited stage disease and those in the broader category. Eight patients are tumour free and alive one year or more after the end of treatment. The median followup is 17 months. Twenty-four patients were delayed 1-2 weeks during treatment because of chemotherapy induced toxicity. Six patients died probably of infection associated with leucopaenia. The majority of the patients' Karnofsky performance improved with the treatment as did their breathlessness assessed on a respiratory score. The short intensive chemotherapy regimen of 3 months produced similar results to those following more prolonged treatment regimens.

Citing Articles

Clostridial myonecrosis in association with etoposide therapy presenting as severe thigh pain.

Smith D, Harris M, Thatcher N Postgrad Med J. 1986; 62(727):403-4.

PMID: 3763552 PMC: 2418713. DOI: 10.1136/pgmj.62.727.403.


Treatment of small cell lung cancer by eight weeks chemotherapy.

Crawford S, Parker D, Glaser M, Southcott B, Begent R, Rustin G Med Oncol Tumor Pharmacother. 1989; 6(4):279-83.

PMID: 2559264 DOI: 10.1007/BF02985162.


Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Henwood J, Brogden R Drugs. 1990; 39(3):438-90.

PMID: 2184009 DOI: 10.2165/00003495-199039030-00008.


An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research.

Rawson N, Peto J Br J Cancer. 1990; 61(4):597-604.

PMID: 2158808 PMC: 1971381. DOI: 10.1038/bjc.1990.133.

References
1.
Cohen M, Creaven P, Fossieck Jr B, Broder L, SELAWRY O, Johnston A . Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep. 1977; 61(3):349-54. View

2.
Spittle M . Methotrexate and radiation. Int J Radiat Oncol Biol Phys. 1978; 4(1-2):103-7. DOI: 10.1016/0360-3016(78)90123-2. View

3.
Oldham R, Greco F . Small-cell lung cancer. A curable disease. Cancer Chemother Pharmacol. 1980; 4(3):173-7. DOI: 10.1007/BF00254014. View

4.
Ihde D, Makuch R, Carney D, Bunn P, Cohen M, Matthews M . Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy. Am Rev Respir Dis. 1981; 123(5):500-7. DOI: 10.1164/arrd.1981.123.5.500. View

5.
Aisner J, Whitacre M, Van Echo D, Wiernik P . Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations. Cancer Treat Rep. 1982; 66(2):221-30. View